Max Healthcare Institute Share Price

NSE
MAXHEALTH •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Max Healthcare Institute Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
9.1
TTM PE Ratio
High in industry
107
Price to Book Ratio
High in industry
13.5
Dividend yield 1yr %
Low in industry
0.1
TTM PEG Ratio
PEG TTM is much higher than 1
15.4

Max Healthcare Institute Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Max Healthcare Institute Ltd Quarterly Revenue

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
1707.46 Cr
1542.95 Cr
1422.9 Cr
1334.97 Cr
1363.16 Cr

Max Healthcare Institute Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
5584.09 Cr
4701.84 Cr
4058.82 Cr
2619.41 Cr
1107.11 Cr

Max Healthcare Institute Ltd Quarterly Net Profit/Loss

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
281.81 Cr
236.27 Cr
251.54 Cr
289.34 Cr
276.68 Cr

Max Healthcare Institute Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
1057.64 Cr
1103.51 Cr
605.05 Cr
-114.5 Cr
12.91 Cr

Max Healthcare Institute Ltd shareholding Pattern

Promoter
23.7%
Foreign Institutions
57.3%
Mutual Funds
11.6%
Domestic Institutions
15.1%
Public
3.8%
Promoter
23.7%
Foreign Institutions
57%
Mutual Funds
12.2%
Domestic Institutions
15.4%
Public
3.9%
Promoter
23.8%
Foreign Institutions
57.3%
Mutual Funds
12.3%
Domestic Institutions
15%
Public
4%
Promoter
23.8%
Foreign Institutions
60.7%
Mutual Funds
10.6%
Domestic Institutions
11.5%
Public
4%
Promoter
23.8%
Foreign Institutions
60.4%
Mutual Funds
10.6%
Domestic Institutions
11.4%
Public
4.4%
Promoter
23.8%
Foreign Institutions
59.9%
Mutual Funds
11.3%
Domestic Institutions
11.9%
Public
4.4%

Max Healthcare Institute Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
14
Bearish Moving Averages
2
5Day EMA
1,175.70
10Day EMA
1,156.80
12Day EMA
1,147.80
20Day EMA
1,116.60
26Day EMA
1,098.60
50Day EMA
1,050.80
100Day EMA
993.30
200Day EMA
913.80
5Day SMA
1,186.60
10Day SMA
1,164.70
20Day SMA
1,093.90
30Day SMA
1,069.60
50Day SMA
1,030.20
100Day SMA
971.90
150Day SMA
940.60
200Day SMA
903.40
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
2844495 Rs
3755284 Rs
Week Rs
1869151 Rs
2657445 Rs
Month Rs
1658695 Rs
2504091 Rs
Resistance & Support
1,174.98
Pivot
Resistance
First Resistance
1,190.22
Second Resistance
1,215.23
Third Resistance
1,230.47
Support
First Support
1,149.97
Second support
1,134.73
Third Support
1,109.72
Relative Strength Index
65.90
Money Flow Index
74.48
MACD
49.10
MACD Signal
42.48
Average True Range
37.72
Average Directional Index
35.26
Rate of Change (21)
17.68
Rate of Change (125)
25.53

Max Healthcare Institute Ltd Company background

Founded in: 2001
Managing director: Abhay Soi
Max Healthcare Institute Limited was originally incorporated as Infinitum Technologies Private Limited at New Delhi, India as a Private Limited Company dated June 18 ,2001. Pursuant to a Fresh Certificate of Incorporation dated June 28, 2002, the name of Infinitum Technologies Private Limited was changed to Max Healthcare Institute Private Limited. Thereafter, pursuant to a Special Resolution dated May 16, 2002 and a fresh Certificate of Incorporation dated October 18, 2002, the Company converted to a Public Limited, and name was changed to Max Healthcare Institute Limited. The Company is primarily engaged in provision of healthcare services through primary care clinics, multi speciality hospitals / medical centres and superspeciality Hospitals facilities. The Company is a leading hospital chains in India with major concentration in North India consisting of a network of 13 network healthcare facilities, which includes BLK Hospital and BNH Hospital. Besides, it provides healthcare services across secondary and tertiary care specialties with key focus on centres of excellence i.e., oncology, neurosciences, cardiac sciences, orthopaedics,renal sciences, liver and biliary sciences and minimal access metabolic and bariatric surgery (MAMBS).In addition to core hospital business, the company has two SBUs, namely, MaxHome and MaxLab. MaxHome is a platform that provides health and wellness services at home. It has 12 service lines, including pathology, pharmacy delivery, physiotherapy and critical care nursing. MaxLab offers pathology services to patients outside of hospitals through a variety of channels including third party hospital laboratory management. Eight hospitals and five medical centres are located in Delhi and the NCR, and the others are located in cities of Mumbai, Mohali, Bathinda and Dehradun. They provide diagnostic, pathology, radiology, radiation oncology and clinical services in select specialties/ departments through deployment of doctors and other medical staff in 4 Partner Healthcare Facilities.In addition, it has established a representative office in Nairobi, Kenya under the name True Max Healthcare which helps in partnering with local hospitals, conducting OPDs, assisting the potential patients with medical visas and pre travel preparation and participating in local events to build its brand internationally. In the year 2000, the Company opened first Medcentre with outpatient facilities and day care surgeries at Max Medcentre, Panchsheel Park.In the year 2002, there were facilities opened in Pitampura and Noida subject to hospital in Pitampura became the first ISO certified hospital for highend secondary care.In 2004, the Company opened its first super tertiary care facility with advanced cardiac life support ambulances and air evacuation service at Max Heart Vascular Institute, Saket. In 2005, multispeciality tertiary care centre in East Delhi with 147 beds, three operation theatres and 1 cardiac catheterization laboratory at Max Hospital, Patparganj were opened by the Company. In 2006, there was opening of first super speciality tertiary care location at Max Super Speciality Hospital Saket.The Company received NABH and NABL certification for laboratories and simultaneously opened a highend secondary care hospital at Gurgaon in the year of 2007.The BLK Hospital was redeveloped and relaunched as a multi super speciality facility by the Company in 2009.On 05 August 2009, through a concession agreement, the Company entered into a public private partnership (PPP) with the Department of Health and Family Welfare (DHFW), Government of Punjab and HBPL (Hometrail Buildtech Private Limited), the Companys subsidiary merged with HEPL (Hometrail Estate Private Limited), for development of greenfield super speciality hospital in Bathinda, Punjab, which was engaged in the development of greenfield super speciality hospital in Mohali, Punjab.In 2010, the BLK Hospital received NABH accreditation and therby the Company opened a 300 bedded hospital in Shalimar Bagh. In 2011, the Company thru HBPL, extended its footprint in North India through a public private partnership with State Government of Punjab with setting up of hospitals in Mohali and Bathinda. In 2012, the first super speciality hospital in Uttarakhand, Max Super Speciality Hospital, Dehradun was opened and the Companys BLK Hospital installed Asia Pacific regions first cyberknife VSI an ultra modern latest generation PETCT to aid accurate diagnosis.In 2013, the BLK Hospital commenced liver and kidney transplant services. Max Healthcare successfully performed 100 bone marrow transplant surgeries within a span of 24 months and landmark surgery on separating two conjoint Nigerian twins respectively. On 28 May 2015, the Company acquired controlling stake in Crosslay Remedies Limited (CRL), a subsidiary that owns and operates a 378 bedded hospital with 328 operational beds, located in East DelhiGhaziabadNoida corridor. The Company further had acquired 51% stake in Saket City Hospitals Private Limited, a subsidiary of the Company (SCHPL), pursuant to which it became a subsidiary in 2015.In 2016, the company launched its vertical, MaxHome, Max Lab and Indias first oncology daycare center at Lajpat Nagar to provide chemotherapy to oncology patients outside the hospital, first standalone immigration center at Lajpat Nagar, New Delhi, the ResponderonBike initiative, Max Centre for Liver and Biliary Sciences and oncology dedicated wing in Max Hospital Shalimar Bagh.In 2017, Max Super Speciality Hospital, Shalimar Bagh introduced advanced silent MRI and intraoperative and portable CT scanner with navigation, it became the first hospital in the network to get accredited by the Joint Commission International (JCI).The Company incorporated MHC Global Healthcare (Nigeria) Limited (MGHL) in Lagos, Nigeria as a wholly owned subsidiary onMay 20, 2019.The Honble National Company Law Tribunal, Mumbai Bench (NCLT) vide its order dated January 17, 2020 sanctioned the Composite Scheme of Amalgamation and Arrangement amongst erstwhile Max India Limited, the Company, Radiant, Max India Ltd. (formerly known as Advaita Allied Health Services Limited) and their respective shareholders and creditors and the Scheme was effective from June 1, 2020. Subsequent to the effective date, healthcare business of Radiant was demerged into the Company and also, residual erstwhile Max India Ltd. (i.e. post demerger of allied health and associated services into Advaita Allied Health Services Limited) which comprises of healthcare activities amalgamated with the Company. Post demerger and amalgamation, the Company became the second largest healthcare delivery chain in India (considering only income from healthcare services aggregated for Company, Radiant and Partner Healthcare Facilities). Further, pursuant to the Scheme, equity shares of the Company were listed on the BSE Limited and National Stock Exchange of India Limited (NSE) on August 21, 2020.As on March 31, 2021, the Company has 6 subsidiaries.The current Promoters of the Company are Mr. Analjit Singh, Ms. Neelu Analjit Singh, Ms. Piya Singh, Mr. Veer Singh, Ms. Tara Singh Vachani, MVIHPL, Mr. Abhay Soi and Kayak Investments Holding Pte. Ltd. Pursuant to Scheme, Analjit Singh Group is to be reclassified as public shareholders in accordance with the provisions of the Listing Regulations (such reclassification, the Depromoterisation). Such Depromoterisation will be undertaken only upon the Company achieving the MPS requirement as prescribed under the SCRR. Post such Depromoterisation, Mr. Abhay Soi and Kayak shall be the Promoters of the Company.During the year 2022, the Company acquired 26% stake in Eqova Healthcare Private Limited to expand its network footprint in East Delhi with addition of 400 beds on February 10, 2022. It also entered into a long term exclusive Operation and Management Agreement with Muthoot Hospitals Private Limited for an upcoming hospital at Dwarka, New Delhi on January 20, 2022. On October 4, 2021, the Company purchased two parcels of land admeasuring 5.26 acres and 6.11 acres, in Gurugram, Haryana on freehold basis for setting up two hospitals and expand the bed capacity of the Company in NCR region by 1000 beds.Kayak Investments Holding Pte. Limited, one of the Promoters of the Company sold 27,26,754 equity shares and consequent to the open market sale, it complied with the MPS norms within the prescribed timelines i.e. with effect from August 20, 2021. As a result, at the end of FY 2122, the public shareholding in the Company stood at 49.36%.Pursuant to Composite Scheme of Amalgamation and Arrangement amongst erstwhile Max India Limited, the Company, Radiant Life Care Private Limited, Max India Limited (formerly known as Advaita Allied Health Services Limited) and their respective shareholders and creditors effective from June 1, 2020, certain persons / entity belonging to Promoter / Promoter Group of the Company i.e. Max Ventures Investment Holdings Private Limited, Mr. Analjit Singh, Ms. Piya Singh, Ms. Neelu Analjit Singh, Ms. Tara Singh Vachani and Mr. Veer Singh have been reclassified as Public Category with the approval accorded by stock exchanges viz. BSE Limited and National Stock Exchange of India Limited (NSE) vide their letters dated March 24, 2022. Therefore, 4,06,229 equity shares of the Companyheld by the above Promoter/ Promoter Group in aggregate, representing 0.04% of its total issued and paid up capital at that time, have been reclassified into Public from Promoters / Promoter Group category with effect from March 24, 2022. Subsequent to reclassification of Promoter / Promoter Group, the Company has only 2 Promoters i.e. Mr. Abhay Soi and Kayak.The Company commissioned 92bedded Oncology Block at Max Super Speciality Hospital, in Shalimar Bagh in March, 2023. In 2023, a cloud deployment was undertaken for two key locations, including Max Lajpat Nagar and Max Panchsheel. During FY23, MaxHome, with the vision of Digital First, launched Instant Doctor Consultation service.
Read More

Max Healthcare Institute Ltd FAQs

Max Healthcare Institute Ltd shares are currently priced at 1165.2 on NSE and 1166.6 on BSE as of 12/19/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Max Healthcare Institute Ltd [MAXHEALTH] share was 79.19. The Max Healthcare Institute Ltd [MAXHEALTH] share hit a 1-year low of Rs. 630.9 and a 1-year high of Rs. 1215.55.

The market cap of Max Healthcare Institute Ltd is Rs. 113272.83 Cr. as of 12/19/2024 12:00:00 AM.

The PE ratios of Max Healthcare Institute Ltd is 144.38 as of 12/19/2024 12:00:00 AM.

The PB ratios of Max Healthcare Institute Ltd is 14.27 as of 12/19/2024 12:00:00 AM

The Mutual Fund Shareholding was 11.56% at the end of 12/19/2024 12:00:00 AM.

You can easily buy Max Healthcare Institute Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -